Humacyte, Inc.
NASDAQ: HUMAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laura E. Niklason
- Employees
- 218
- Headquarters
- Durham, United States
- IPO year
- 2020
- Market cap
- $12.0M
- Website
- https://humacyte.com
Loading HUMAW…
Loading profile data…Frequently asked questions about HUMAW
What does Humacyte, Inc. (HUMAW) do?
Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas. The company employs its...
Where does HUMAW trade?
Humacyte, Inc. (HUMAW) trades on the NASDAQ Global Select.
What sector is HUMAW in?
Humacyte, Inc. (HUMAW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Humacyte, Inc.?
Laura E. Niklason is the chief executive officer of Humacyte, Inc. (HUMAW).
Where is Humacyte, Inc. headquartered?
Humacyte, Inc. is headquartered in United States.
Does HUMAW pay a dividend?
Humacyte, Inc. (HUMAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HUMAW go public?
Humacyte, Inc. (HUMAW) completed its initial public offering in 2020.